Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

doi:10.1093/ije/dyad146

. 2023 Dec 25;52(6):e364-e373.

doi: 10.1093/ije/dyad146.

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

Andre F S Amaral^{1

2}, James Potts¹, Ben Knox-Brown¹, Emmanouil Bagkeris¹, Imed Harrabi³, Hamid Hacene Cherkaski⁴, Dhiraj Agarwal⁵, Sanjay Juvekar⁵, Mahesh Padukudru Anand⁶, Thorarinn Gislason^{7

8}, Asaad Ahmed Nafees⁹, Kevin Mortimer^{10

11}, Christer Janson¹², Li Cher Loh¹³, Stefanni Nonna Paraguas¹⁴, Meriam Denguezli¹⁵, Mohammed Al Ghobain^{16

17}, David Mannino^{18

19}, Martin W Njoroge^{20

21}, Graham Devereux²¹, Terence Seemungal²², Cristina Barbara²³, Ali Kocabaş²⁴, Rana Ahmed²⁵, Althea Aquart-Stewart²⁶, Michael Studnicka²⁷, Tobias Welte²⁸, Wan C Tan²⁹, Richard N van Zyl-Smit^{30

31}, Parvaiz Koul³², Vanessa Garcia-Larsen³³, Cosetta Minelli^{1

2}, A Sonia Buist³⁴, Peter Burney¹; BOLD Study Collaborative Network

Collaborators, Affiliations

PMID: 37862437
PMCID: PMC10749748
DOI: 10.1093/ije/dyad146

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

Andre F S Amaral et al. Int J Epidemiol. 2023.

. 2023 Dec 25;52(6):e364-e373.

doi: 10.1093/ije/dyad146.

PMID: 37862437
PMCID: PMC10749748
DOI: 10.1093/ije/dyad146

No abstract available

Keywords: Chronic obstructive pulmonary disease; global health; non-communicable respiratory disease.

PubMed Disclaimer

Conflict of interest statement

D.M. is a consultant to GlaxoSmithKline, AstraZeneca and Up-to-Date, a shareholder of GlaxoSmithKline, and an expert witness on behalf of people suing the tobacco industry. T.S. has received honoraria from AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim for lecturing and attendance at advisory boards over the past 3 years, and has published research with GlaxoSmithKline in the past year. W.C.T. reports grants from Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants 93326) with industry partners Astra Zeneca Canada, Boehringer-Ingelheim Canada, GlaxoSmithKline Canada, Merck, Novartis Pharma Canada, Nycomed Canada, Pfizer Canada, during the conduct of the CanCOLD study; personal fees from GlaxoSmithKline, Canada, and from Astrazeneca, Canada, outside the submitted work.

Figures

**Figure 1.**
Burden of Obstructive Lung Disease (BOLD) study sites

**Figure 2.**
Selection of participants in the Burden of Obstructive Lung Disease (BOLD) cohort

See this image and copyright information in PMC

Cited by

Isolated small airways obstruction predicts future chronic airflow obstruction: a multinational longitudinal study.
Knox-Brown B, Potts J, Santofimio VQ, Minelli C, Patel J, Abass NM, Agarwal D, Ahmed R, Mahesh PA, Bs J, Denguezli M, Franssen F, Gislason T, Janson C, Juvekar SK, Koul P, Malinovschi A, Nafees AA, Nielsen R, Paraguas SNM, Buist S, Burney PG, Amaral AFS. Knox-Brown B, et al. BMJ Open Respir Res. 2023 Nov;10(1):e002056. doi: 10.1136/bmjresp-2023-002056. BMJ Open Respir Res. 2023. PMID: 37989490 Free PMC article.
Chronic respiratory disease observatory for Africa (CHEST-Africa): study protocol for the prevalence, determinants and economic impacts of asthma and COPD in Africa.
Ozoh OB, Ndimande N, Amaral AFS, Lesosky M, Mbonigaba J, Stolbrink M, Zurba L, Ayo-Olagunju T, Kayembe-Kitenge T, Lakoh S, Mocumbi A, Mohammed J, Nantanda R, Nunes E, Ouédraogo AR, Owusu S, Sibomana JP, Masekela R, Mortimer K. Ozoh OB, et al. BMJ Open Respir Res. 2024 Jul 17;11(1):e002416. doi: 10.1136/bmjresp-2024-002416. BMJ Open Respir Res. 2024. PMID: 39019625 Free PMC article.
Concordance between FVC and FEV₆ for identifying chronic airflow obstruction and spirometric restriction in the Burden of Obstructive Lung Disease (BOLD) study.
Knox-Brown B, Potts J, Franssen FME, Nielsen R, Denguezli M, Rotevatn AØ, Juvekar SK, Cherkaski HH, Studnicka M, Sylvester KP, Mortimer K, Bateman ED, Janson C, Malinovschi A, Seemungal T, Koul P, Mannino D, Mahesh PA, Jogi R, Mejza F, Al Ghobain M, Paraguas SNM, Welte T, Wouters E, Gislason T, Harrabi I, Dias H, Obaseki DO, Kocabas A, Barbara C, Cardoso J, Agarwal D, Nafees AA, Rodrigues F, Garcia-Larsen V, Erhabor GE, Loh LC, Amaral AFS; BOLD collaborative research group. Knox-Brown B, et al. BMJ Open Respir Res. 2025 Jul 13;12(1):e002355. doi: 10.1136/bmjresp-2024-002355. BMJ Open Respir Res. 2025. PMID: 40659415 Free PMC article.
Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study.
Janson C, Potts J, Malinovschi A, Agarwal D, Ahmed R, Aquart-Stewart A, Harrabi I, Denguezli M, Devereux G, Erhabor GE, Gislason T, Jogi R, Juvekar SK, Knox-Brown B, Koul P, Mortimer K, Nafees AA, Nielsen R, Mahesh PA, Paraguas SNM, Rotevatn AØ, Sooronbaev T, Burney PGJ, Amaral AFS; BOLD Collaborative Research Group. Janson C, et al. BMJ Open Respir Res. 2025 Jan 19;12(1):e002442. doi: 10.1136/bmjresp-2024-002442. BMJ Open Respir Res. 2025. PMID: 39832891 Free PMC article.
Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study.
Abozid H, Patel J, Burney P, Hartl S, Breyer-Kohansal R, Mortimer K, Nafees AA, Al Ghobain M, Welte T, Harrabi I, Denguezli M, Loh LC, Rashid A, Gislason T, Barbara C, Cardoso J, Rodrigues F, Seemungal T, Obaseki D, Juvekar S, Paraguas SN, Tan WC, Franssen FME, Mejza F, Mannino D, Janson C, Cherkaski HH, Anand MP, Hafizi H, Buist S, Koul PA, El Sony A, Breyer MK, Burghuber OC, Wouters EFM, Amaral AFS; BOLD Collaborative Research Group. Abozid H, et al. EClinicalMedicine. 2024 Jan 21;68:102423. doi: 10.1016/j.eclinm.2024.102423. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38268532 Free PMC article.

See all "Cited by" articles

References

1. Davis RM, Novotny TE.. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S82–84. - PubMed
1. Siafakas NM, Vermeire P, Pride NB. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398–420. - PubMed
1. Cunningham J, Condon JR.. Premature mortality in aboriginal adults in the Northern Territory, 1979-1991. Med J Aust 1996;165:309–12. - PubMed
1. Burney P, Patel J, Minelli C. et al.; BOLD Collaborative Research Group. Prevalence and population-attributable risk for chronic airflow obstruction in a large multinational study. Am J Respir Crit Care Med 2021;203:1353–65. - PMC - PubMed
1. Murray CJ, Lopez AD.. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–76. - PubMed

MeSH terms

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Davis RM, Novotny TE.. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S82–84. - PubMed

[2] Davis RM, Novotny TE.. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S82–84. - PubMed

[3] Siafakas NM, Vermeire P, Pride NB. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398–420. - PubMed

[4] Siafakas NM, Vermeire P, Pride NB. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398–420. - PubMed

[5] Cunningham J, Condon JR.. Premature mortality in aboriginal adults in the Northern Territory, 1979-1991. Med J Aust 1996;165:309–12. - PubMed

[6] Cunningham J, Condon JR.. Premature mortality in aboriginal adults in the Northern Territory, 1979-1991. Med J Aust 1996;165:309–12. - PubMed

[7] Burney P, Patel J, Minelli C. et al.; BOLD Collaborative Research Group. Prevalence and population-attributable risk for chronic airflow obstruction in a large multinational study. Am J Respir Crit Care Med 2021;203:1353–65. - PMC - PubMed

[8] Burney P, Patel J, Minelli C. et al.; BOLD Collaborative Research Group. Prevalence and population-attributable risk for chronic airflow obstruction in a large multinational study. Am J Respir Crit Care Med 2021;203:1353–65. - PMC - PubMed

[9] Murray CJ, Lopez AD.. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–76. - PubMed

[10] Murray CJ, Lopez AD.. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–76. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical